Breaking Short Interest: Time to Reconsider Biotime Incorporated (NYSEMKT:BTX) After More Short Sellers?

November 28, 2016 - By Hazel Jackson   ·   0 Comments

Breaking Short Interest: Time to Reconsider Biotime Incorporated (NYSEMKT:BTX) After More Short Sellers?

The stock of Biotime Incorporated (NYSEMKT:BTX) registered an increase of 0.6% in short interest. BTX’s total short interest was 5.43M shares in November as published by FINRA. Its up 0.6% from 5.40 million shares, reported previously. With 119,100 shares average volume, it will take short sellers 46 days to cover their BTX’s short positions. The short interest to Biotime Incorporated’s float is 8.65%. About 118,567 shares traded hands. BioTime, Inc. (NYSEMKT:BTX) has risen 18.69% since April 25, 2016 and is uptrending. It has outperformed by 12.67% the S&P500.

BioTime, Inc. is a clinical-stage biotechnology company. The company has a market cap of $341.47 million. The Firm is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. It has a 15.65 P/E ratio. The Firm is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research.

Insitutional Activity: The institutional sentiment increased to 2.67 in Q2 2016. Its up 0.42, from 2.25 in 2016Q1. The ratio increased, as 3 funds sold all BioTime, Inc. shares owned while 13 reduced positions. 9 funds bought stakes while 27 increased positions. They now own 38.13 million shares or 10.80% more from 34.42 million shares in 2016Q1.
Artal Sa last reported 1.28M shares in the company. D E Shaw Inc owns 16,615 shares or 0% of their US portfolio. Blackrock Institutional Na accumulated 1.93M shares or 0% of the stock. Blackrock Advisors Limited Liability Corporation owns 30,186 shares or 0% of their US portfolio. Geode Mgmt Limited Co has 0% invested in the company for 370,251 shares. Carroll Fincl Associates Incorporated has 0.01% invested in the company for 17,000 shares. Guggenheim Capital Limited Liability Company owns 24,622 shares or 0% of their US portfolio. Douglass Winthrop Advsr Lc holds 15,000 shares or 0% of its portfolio. Bankshares Of New York Mellon Corp has invested 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX). Amer Intll Incorporated has invested 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX). Pnc Group Inc last reported 80,300 shares in the company. Ladenburg Thalmann Finance Inc has 0% invested in the company for 825 shares. Principal Financial Group Inc has 0% invested in the company for 11,249 shares. State Board Of Administration Of Florida Retirement Sys holds 0% or 22,784 shares in its portfolio. Financial Bank Of America De last reported 0% of its portfolio in the stock.

BTX Company Profile

BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Firm is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Firm is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company’s pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient’s own somatic or adult stem cells, at the desired location.

More notable recent BioTime, Inc. (NYSEMKT:BTX) news were published by: Businesswire.com which released: “BioTime, Inc. to Report Second Quarter Results on August 9, 2016” on July 27, 2016, also Businesswire.com with their article: “Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring …” published on January 12, 2016, Quotes.Wsj.com published: “News BioTime Inc.BTX” on February 12, 2011. More interesting news about BioTime, Inc. (NYSEMKT:BTX) were released by: Businesswire.com and their article: “BioTime, Inc. Announces Proposed Public Offering of Common Stock” published on June 15, 2016 as well as Businesswire.com‘s news article titled: “BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over …” with publication date: July 05, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>